AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05880940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Arm and Hand Exercise Program
Description: These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at ARU. These exercises will be monitored and supervised by therapists who have been trained in the study protocol. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study. For this study, the investigators ask participants to exercise following this customized arm and hand exercise program for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit.
Study NCT05119621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS application
Description: Assigned Interventions: In addition to the standard pain management applied in the clinic, TENS will be applied to children who have had surgery.
Study NCT06428487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolgolimab
Description: Prolgolimab infusions 1 mg/kg
Study NCT05839041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVD-104
Description: Intravitreal injection
Study NCT05839041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVD-104
Description: Intravitreal injection
Study NCT05839041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avacincaptad
Description: Intravitreal injection of 2 mg avacincaptad
Study NCT06286254 — intervention group
Intervention type: DRUG
Intervention: Cycloferone
Description: Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
Study NCT05908344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activated Sleep Pad system (Frequen-ZZZ)
Description: The investigational device is a sleep pad and bedside controller system capable of producing a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect. The field potentials generated by the pad are hypothesized to have benefit for sleep.
Study NCT05908344 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deactivated Sleep Pad system (Frequen-ZZZ)
Description: The investigational device is a sleep pad and bedside controller system that produces a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
Study NCT04979052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Gamma-1B
Description: 100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
Study NCT06506565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Infusion during wound care
Study NCT06506565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: Infusion during wound care
Study NCT05891353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Water Immersion
Description: Cold Water Immersion task of hand
Study NCT05891353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Inducing Stretch
Description: Moderately painful stretch of the neck
Study NCT05891353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Free Stretch
Description: Pain free stretch of the neck
Study NCT05901246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS-containing dietary supplement
Description: Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)
Study NCT05901246 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachet containing the excipients of the ingredient (2,25 g placebo/day)
Study NCT05965440 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
Description: Analysis of microbiota
Study NCT05944016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin (standard dose 10 mg p.o. once daily)
Study NCT05944016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (standard dose p.o. once daily)
Study NCT05726045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard smoking cessation program (SCP)
Description: Each subject will receive a standard SCP as group treatment once a week (1h) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer, 2004), and will be carried out by a qualified therapist.
Study NCT05726045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard smoking cessation program (SCP)
Description: Each subject will receive a standard SCP as group treatment once a week (1h) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer, 2004), and will be carried out by a qualified therapist.
Study NCT05726045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation treatment (CRT)
Description: The cognitive remediation treatment (CRT) employs a chess-based battery of tasks (delivered through an app-based online tool), two times per week over six weeks (60min duration per session).
Study NCT05726045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation treatment (CRT)
Description: The cognitive remediation treatment (CRT) employs a chess-based battery of tasks (delivered through an app-based online tool), two times per week over six weeks (60min duration per session).
Study NCT05726045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT evening)
Description: The high-intensity interval training will be delivered through an app environment with several choices of exercise, two times per week over six weeks.~The training will include a 5-minutes warm-up and cool down phase. In between, participants will perform four 4-minutes blocks of exercise at high intensity, interspersed with three 3-minute blocks of low intensity (total of 35 minutes exercise).
Study NCT05592067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I tape technique
Description: I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
Study NCT05592067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Button hole technique
Description: Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
Study NCT05592067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: exercises will be taught to the patient and a total of 21 sessions will be applied once a day
Study NCT05592067 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercises
Description: exercises will be taught to the patient and a total of 21 sessions will be applied once a day
Study NCT06449950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Verbal Oral Hygiene Instructions
Description: OHI-S index scores of patients who received verbal oral hygiene education were measured at baseline and final (in post-education).
Study NCT06449950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Video-Based Oral Hygiene Instructions
Description: OHI-S index scores of patients who received video-based oral hygiene education were measured at baseline and final (in post-education).
Study NCT05257408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 80 mg/m^2
Description: Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.
Study NCT05257408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant 150 mg once daily (QD)
Description: Relacorilant is administered as capsules for oral dosing.
Study NCT05257408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel 100 mg/m^2
Description: Nab-paclitaxel is administered as IV infusion on Day 1, 8, and 15 of each 28-day cycle.
Study NCT05798078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Interpretation (CBM-I)
Description: The CBM-I intervention is based on the interpretation training paradigm developed by Mathews and Mackintosh (2000). It comprises a series of training scenarios describing different (mostly everyday) socially-relevant situations, structured so they start ambiguously but always have a positive ending. The positive ending is presented as word fragment, which participants are instructure to complete. In about 25% of trials, participants are further requested to respond to comprehension questions about the scenario presented. Each CBM-I session comprises 45 trials presented in 5 blocks of 9 scenarios.
Study NCT05798078 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training Control Condition
Description: The sham training is in an identical format to the CBM-I training, except that the scenarios are all entirely neutral, with no reference to social situations and no emotional ambiguity.
Study NCT06044337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: Administered as specified in the treatment arm.
Study NCT05458024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 2
Description: 300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules.
Study NCT05458024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D2 Placebo
Description: Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU
Study NCT05874713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N8c on Day 1
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
Study NCT05874713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 1
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
Study NCT05874713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N8c on Day 22
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
Study NCT05874713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 22
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
Study NCT05874713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N8c on Day 202
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
Study NCT05070039 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Expression of Cortactin anti body
Description: assessment of Cortactin immunohistochemical expression in invasive and non-invasive urothelial carcinoma.
Study NCT05929560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional impression
Description: Palatal impressions obtained using an irreversible hydrocolloid impression material
Study NCT05929560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital impression
Description: after obtaining stone models from conventional impression material, stone models were scanned using the I700 (Medit) scanner and Patients were directly scanned intraorally using an intraoral 3D scanner Subsequently, the printed 3D model scan data of the seven patients were then used for standard triangulated language (STL)
Study NCT05089409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651, 2 mg/mL
Description: The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Study NCT05089409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651, 5 mg/mL
Description: The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Study NCT05089409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651, 10 mg/mL
Description: The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Study NCT05089409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651, 20 mg/mL
Description: The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Study NCT05089409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATB1651, 30 mg/mL
Description: The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Study NCT05089409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days
Study NCT06472583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: Preoperative immunotherapy (200 mg, infusion every 21 days, 4 administrations planned)
Study NCT06472583 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative radiation therapy
Description: Boost of preoperative robotic stereotactic radiotherapy
Study NCT06472583 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Description: Boost of preoperative robotic stereotactic radiotherapy
Study NCT06472583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9% NaCl in the volume 100 ml
Study NCT04433351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enriched rehabilitation
Description: The enriched rehabilitation is based on the use of sensory-motor integration in addition to conventional speech therapy. The sensory-motor integration method is based on the Ultraspeech-player software. This software allows therapists to display movements of speech articulators (tongue and lips) recorded on a reference speaker during production of vowels or consonants (isolated or combined). Sagittal movements of the tongue are recorded using ultrasound and front views of lip movements are captured through video imaging.~During rehabilitation with the Ultraspeech-player software, patients will be seated in front of a computer screen, observe articulatory movements and listen to phonemes. Then, they will be required to repeat each of them five times and move on to the next phoneme, with the agreement of the experimenter.
Study NCT04433351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple rehabilitation
Description: The simple rehabilitation is based on conventional speech therapy. The conventional speech therapy will be provided by the speech therapist. Classically, the speech therapist uses word production with repetition and naming exercises. The therapist will show the patient series of pictures associated or not with written words, and the patient is required to name them and/or read aloud the word. In case of impossibility to perform the task, the therapist may can help the patient by using the indexing method or by asking the patient to repeat after him/her. According to patient's competencies and progress, the difficulty of reeducation can increase progressively.
Study NCT06584071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: PM8002 via IV infusion, Q3W
Study NCT06584071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1009
Description: PM8002 via IV infusion, Q3W
Study NCT06584071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atezolizumab
Description: atezolizumab,1200mg, via IV infusion, Q3W
Study NCT06584071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab,15mg/kg, via IV infusion, Q3W
Study NCT05522049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperangulated videolaryngoscope
Description: Intubation using a hyperangulated videolaryngoscope
Study NCT05522049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh videolaryngoscope
Description: Intubation using a Macintosh videolaryngoscope
Study NCT05488665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crush technique
Description: Treatment for bifurcation with the Crush technique
Study NCT05488665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Culotte technique
Description: Treatment for bifurcation with the culotte technique
Study NCT06404450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital CBT
Description: The digital CBT program is called Daylight (Big Health, Ltd). The program employs a virtual therapist to guide individuals through interactive exercises and animations to facilitate the learning and implementation of CBT techniques. The program focuses on four modules (10-20 minutes each) which address specific CBT principles: stimulus control, applied relaxation, cognitive restructuring (decatastrophizing), and imaginal exposure. Daylight is designed to be self-paced, with the app encouraging users to practice techniques both within the app and in real-life situations on a daily basis. Users receive reminders and motivational messages via emails, push notifications, and text messages tailored to participant progress.
Study NCT06088121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATNC MDD-V1 (Real TMS + Real Cog)
Description: Synchronized TMS and cognitive stimulation to 6 brain areas.
Study NCT06088121 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ATNC MDD-V1 (Sham TMS + Real Cog)
Description: Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
Study NCT06088121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATNC BN-V1
Description: The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
Study NCT06088121 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ATNC BN-V1
Description: The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
Study NCT06088121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATNC BN-V2
Description: The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
Study NCT06088121 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ATNC BN-V2
Description: The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
Study NCT06496763 — intervention group
Intervention type: DEVICE
Intervention: Vision-700
Description: OCT machines used for diagnostic purposes
Study NCT05386420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hymecromone tablets
Description: Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.
Study NCT05386420 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Conventional treatment combined with Placebo.
Study NCT05108012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cell therapy
Description: Activated NK cell injection in tumor cavity of patient with GBM (Glioblastoma Multiform)
Study NCT06137937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Intradialytic aerobic exercise for eight weeks
Study NCT05811286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions
Description: With the shaver, the lesion is removed in the OR. We will include endometrial polyps, FIGO 0-1 myomas and retained products of conception.~We will assess the completeness of hysteroscopic resection, operation time, need for cervical dilation, adverse events, pain, operator satisfaction; quality of tissue for histological examination, postoperative complications and pain.